Domestic pharmaceutical companies have failed on the patent nullity of Baraclude
As Daewoong Pharmaceutical and Hanmi Pharmaceutical have failed on the substance patent nullity of Baraclude, domestic pharmaceutical companies’ exclusive sale rights have also been blown away, too.
If the substance patent of Baraclude was nullified, several domestic pharmaceutical companies cou...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
